📢 Brazil and Thailand become the first malaria-endemic countries to launch new single-dose relapse prevention medicine for Plasmodium vivax (P. vivax) malaria
P. vivax is the dominant malaria parasite in many countries outside of sub-Saharan Africa and is characterised by clinical relapses. Without treatment for the latent liver-stage infection, patients experience repeated bouts of illness, imposing significant physical, economic, and social burdens on both individuals and communities. Relapses also increase the disease burden and the potential for onward transmission, ultimately impeding global efforts to eliminate malaria.
Developed through a longstanding partnership Medicines for Malaria Venture, tafenoquine, co-administered with chloroquine, offers a new potential treatment option for vulnerable populations who are disproportionately affected by this disease.
By continuing to invest in global health R&D, strengthening healthcare systems, and enabling access to healthcare in lower-income countries, together with our partners we can help change the trajectory of malaria.
#ChangeTheTrajectory #Malaria #GlobalHealth #ZeroMalaria
President at Kassen Recruitment
2wExciting news for medical advancements!